Margaret Rosenfeld, MD, MPH, Seattle Children’s Research Institute and Department of Pediatrics, University of Washington School of Medicine

Dr. Rosenfeld was a lead investigator in the Phase 3 ARRIVAL study, sponsored by Vertex, which found Ivacaftor (KALYDECO®) is generally safe and effective in patients aged 2 years and older who have cystic fibrosis and specific CFTR mutations. Dr. Rosenfeld noted...

Pin It on Pinterest